Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family
BIO|MASTER.Amvia: Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dörte Vossmeyer, Dr.
- Phone Number: +49 30 68905 1306
- Email: doerte.vossmeyer@biotronik.com
Study Contact Backup
- Name: Konstantinia Skreka, Dr.
- Phone Number: +49 (0) 30 68905-2949
- Email: konstantinia.skreka@biotronik.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Standard indication for de novo, upgrade or replacement pacemaker or cardiac resynchronization therapy pacemaker (CRT-P) implantation
- Ability to understand the nature of the study
- Willingness to provide written informed consent
- Ability and willingness to perform all follow-up visits at the study site
- Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring® concept
Exclusion Criteria:
- Planned for conduction system pacing
- Planned cardiac surgical procedures or interventional measures other than the study procedure within the next 12 months
- Known pregnancy or breast feeding
- Age less than 18 years
- Participation in another interventional clinical investigation
- Life-expectancy less than 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Amvia pacemaker or CRT-P implantation
|
Implantation of a pacemaker or CRT-P devices
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SADE-free rate at 6 months
Time Frame: 6 months
|
Kaplan-Meier estimate of Amvia-related SADE-free rate at 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SADE-free rate at 12 months
Time Frame: 12 months
|
Kaplan-Meier estimate of Amvia-related SADE-free rate at 12 months
|
12 months
|
|
CRT AutoAdapt performance
Time Frame: 12 months
|
CRT AutoAdapt: different pacing percentages
|
12 months
|
|
CRT AutoAdapt AV delay
Time Frame: 12 months
|
Mean adapted AV delay after pace/sense
|
12 months
|
|
Assessment of the CRT AutoAdapt feature (CRT-devices only) by the investigator
Time Frame: 12 months
|
Investigator appraisal of the overall handling of the feature (score: very good/good/ adequate/poor/very poor)
|
12 months
|
|
Auto LV VectorOpt
Time Frame: 12 months
|
Time needed for threshold measurement
|
12 months
|
|
Assessment of the Automatic LV VectorOpt test (CRT-devices only) by the investigator
Time Frame: 2 months
|
Investigator appraisal of the overall handling of the feature (score: very good/good/ adequate/poor/very poor)
|
2 months
|
|
aATP-related ADEs and SADEs
Time Frame: 12 months
|
aATP-related ADEs and SADEs
|
12 months
|
|
Sensing performance of device-based measurements
Time Frame: 12 months
|
The appropriateness of sensing performance will be assessed by calculating the percentage of appropriate sensing for all leads.
|
12 months
|
|
Pacing performance of device-based measurements
Time Frame: 12 months
|
The appropriateness of pacing performance will be assessed by calculating the percentage of appropriate pacing for all leads.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Istvan Szendey, Dr., Kliniken Maria Hilf GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BA114
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.